Adrenomed closes EUR 22 million equity financing to accelerate development of Adrecizumab (HAM8101) and provides business update
- Series E round led by existing top-tier life science investors Wellington Partners and HBM Healthcare Investments
- Data from AdrenOSS-2 on early treatment start with Adrecizumab in septic shock to be presented at DIVI, December 2-4, 2020